StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$161.52+0.73 (+0.45%)

Close on Nov 2, 2026Market cap $308.20BP/E 22.6Yield –

Novartis Net Sales in the U.S. by Quarter

Net Sales in the U.S. ($M)

QuarterlyAnnual

Novartis Net Sales in the U.S.: $156M in Q3 2026, up 2.6% from a year earlier.

Latest, Q3 2026
156
Period ended Sep 30, 2026
Change on a year earlier
+2.6%
152 in Q3 2025
History
16 quarters
Since Q3 2019
Sources
16
Documents cited below

Where the Q3 2026 figure comes from

“|| Lutathera | Oncology | GEP-NETs gastroenteropancreatic neuroendocrine tumors | 156 | 3 | 63 | 3 | 6 | 219 | 3 | 3”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F (Top 20 Brands US / Rest of World).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNet Sales in the U.S. ($M)Year on yearSource
Q3 2026Sep 30, 2026156+2.6%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 2026163+8.7%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 2026151+8.6%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 2025147+6.5%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 2025152+13.4%Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2025Jun 30, 2025150+21.0%Novartis Form 6-K (0001370368-25-000012) ↗
Q1 2025Mar 31, 2025139+18.8%Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2024Dec 31, 2024138+34.0%Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2024Sep 30, 2024134+17.5%Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2024Jun 30, 2024124+17.0%Novartis Form 6-K (0001370368-24-000019) ↗
Q1 2024Mar 31, 2024117+12.5%Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2023Dec 31, 2023103–Novartis Form 6-K (0001370368-24-000007) ↗
Q3 2023Sep 30, 2023114–Novartis Form 6-K (0001370368-23-000068) ↗
Q2 2023Jun 30, 2023106–Novartis Form 6-K (0001370368-23-000059) ↗
Q1 2023Mar 31, 2023104–Novartis Form 6-K (0001370368-23-000046) ↗
Q3 2019Sep 30, 201996–Novartis Form 6-K (0001370368-19-000062) ↗

Breakdown

What makes up net Sales in the U.S.

Cite this data

StockData. (2026). Novartis Net Sales in the U.S. ($M), quarterly Q3 2019–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-lutathera-us-sales

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.